Pathogenesis of diverse clinical and pathological phenotypes in hypertrophic cardiomyopathy

A J Marian1

  • 1Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA. amarian@bcm.tmc.edu

Lancet (London, England)
|January 1, 2000
PubMed

Insights

Cardiac myocyte contractility is decreased in hypertrophic cardiomyopathy, not increased. This contractile deficit stimulates factors leading to hypertrophy and fibrosis, explaining disease variability.

Area of Science:

  • Cardiology
  • Molecular Biology
  • Genetics

Background:

  • Hypertrophic cardiomyopathy (HCM) is characterized by cardiac hypertrophy.
  • Current understanding suggests increased myocardial contractility in HCM.
  • This study proposes an alternative hypothesis for HCM pathogenesis.

Purpose of the Study:

  • To challenge the prevailing view of increased contractility in HCM.
  • To propose that decreased cardiac myocyte contractility is the primary defect in HCM.
  • To link this contractile deficit to the expression of cardiac trophic factors and subsequent phenotypes.

Main Methods:

  • Review of existing literature and proposed hypothesis.
  • Analysis of gene transfer studies in cardiac myocytes from HCM patients.
  • Conceptual framework linking contractility, trophic factors, and HCM phenotypes.

Main Results:

  • Gene transfer studies support impaired contractility and increased trophic factor expression in HCM myocardium.
  • Hypothesis posits that contractile deficit drives trophic factor increase, leading to hypertrophy and fibrosis.
  • Individual variations in trophic factor expression explain phenotypic variability in HCM.

Conclusions:

  • Decreased cardiac myocyte contractility may be the primary driver of HCM.
  • Trophic factors, stimulated by contractile deficits, are key mediators of HCM phenotypes.
  • Further research is needed to measure myocyte contractility, identify trophic factors, and test inhibition strategies in HCM.

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...